Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Field	Value	Language
dc.contributor.author	Rogiers, Aljosja	en
dc.contributor.author	da Silva, Ines Pires	en
dc.contributor.author	Tentori, Chiara	en
dc.contributor.author	Tondini, Carlo Alberto	en
dc.contributor.author	Grimes, Joseph M	en
dc.contributor.author	Trager, Megan H	en
dc.contributor.author	Nahm, Sharon	en
dc.contributor.author	Zubiri, Leyre	en
dc.contributor.author	Manos, Michael	en
dc.contributor.author	Bowling, Peter	en
dc.contributor.author	Elkrief, Arielle	en
dc.contributor.author	Papneja, Neha	en
dc.contributor.author	Vitale, Maria Grazia	en
dc.contributor.author	Rose, Apri	en
dc.date.accessioned	2021-02-09T22:29:30Z
dc.date.available	2021-02-09T22:29:30Z
dc.date.issued	2021
dc.identifier.uri	https://hdl.handle.net/2123/24432
dc.description.abstract	BACKGROUND: Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on t	en
dc.language.iso	en	en
dc.rights	Other
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition	en
dc.type	Article	en
dc.identifier.doi	10.1136/jitc-2020-001931
usyd.faculty	Faculty of Medicine and Health, Sydney Medical School	en

Associated file/s

There are no files associated with this item.